Overall, this finding revealed a novel hypothalamic-pituitary-bone marrow axis as a neuroendocrine pathway that contributed to cancer-induced myelopoiesis and immunosuppression and suggested MC5R as a potential therapeutic target for the treatment of cancers resistant to immune checkpoint therapies in the future. The gene discussed is MC5R; the disease is cancer.